Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations
Year: 2025
Type: article
Source: Blood
Authors: Naranie Shanmuganathan, David T. Yeung, Carol Wadham, Adelina Fernandes, Muneeza Maqsood, NurHezrin Shahrin, Verity Saunders, Rosalie R. Kenyon, Ming Lin, John Toubia, Joe McConnell, Dominic Kaczorowski, David M. Ross, Agnes S. M. Yong, Lynette Chee, Jake Shortt, Nicholas Viiala, Jodi Braley, Chung Hoow Kok, Timothy P. Hughes, Susan Branford
Institutions: South Australia Pathology, Royal Adelaide Hospital, University of South Australia, South Australian Health and Medical Research Institute, Centre for Cancer Biology, Australasian Leukaemia and Lymphoma Group, The University of Adelaide, Flinders University, The University of Western Australia, Royal Perth Hospital, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Monash Medical Centre, Monash Health, Monash University, Liverpool Hospital, UNSW Sydney
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413921753